HBW Insight is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Avastin’s Breast Cancer Claim: Will FDA’s Hamburg Take A Middle Road?

Executive Summary

FDA Commissioner Margaret Hamburg faces a decision on the future of Avastin’s (bevacizumab) first-line metastatic breast cancer claim that may not be so cut and dried as the Oncologic Drugs Advisory Committee’s unanimous vote favoring the indication’s withdrawal suggests.

Related Content

CDER's Rejection Of Larger Bromday Bottle Rests On Hypothetical Risk, ISTA Says
Amid Avastin Noise, Shire Quietly Awaits Word On ProAmatine Public Hearing
Genentech Restricts Population In Last-Ditch Bid To Keep Avastin’s Breast Cancer Claim
NCCN Guidelines Reaffirm Support For Avastin In Metastatic Breast Cancer
Avastin Debate Could Provide Clarity On Use Of Progression-Free Survival Endpoints
Genentech Losing Its Legs? Avastin Study Proposal Undercut By Feasibility, Scientific Concerns
FDA’s NSCLC Guidance Stresses Overall Survival Endpoint, Sets PFS Standards
FDA Thinking "Seriously, Deeply" About Range Of Approval Strategies – Hamburg
After Avastin, Seeking Clarity On Progression-Free Survival Endpoints
New Avastin Breast Cancer Study Proposal Not Enough To Save Current Claim, ODAC Concludes





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts